Inhibikase Therapeutics (IKT) Registration Filing summary

Company overview and business model

• Clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics for cardiopulmonary and neurodegenerative diseases, focusing on aberrant Abelson Tyrosine Kinase signaling.

• Lead programs include IkT-001Pro (a prodrug of imatinib mesylate) for pulmonary arterial hypertension (PAH) and risvodetinib (IKT-148009) for Parkinson's disease and multiple system atrophy (MSA).

• IkT-001Pro is being advanced as a disease-modifying treatment for PAH, with bioequivalence to imatinib mesylate established and a Phase 2b trial planned.

• Risvodetinib has completed a Phase 2 trial in Parkinson's disease, with results expected in Q4 2024, and is being developed for MSA with Orphan Drug Designation.

• The company holds commercialization rights to all programs and patent protection in the U.S. until at least 2033 for IkT-001Pro and 2036 for risvodetinib.

Financial performance and metrics

• Closed a private placement in October 2024, raising approximately $110 million, with potential aggregate financing up to $275 million upon full warrant exercise.

• No revenue from product sales to date; operations have been funded by equity offerings and grants.

• Significant net losses since inception and expects to continue incurring losses for the foreseeable future.

Use of proceeds and capital allocation

• Net proceeds from the October 2024 private placement are intended to finance the Phase 2b trial in PAH and for general corporate purposes.

• Proceeds from the resale of shares by selling stockholders will not go to the company; only proceeds from warrant exercises, if any, will be received.